In addition, based on the antiatherogenic properties of PON1 and its ability to quell LDL susceptibility to oxidation, numerous studies indicated that the evaluation of PON1 activity represents a helpful approach to monitor pharmacological and nutritional antioxidant treatments in CKD [13,78,80,82,83,111]. The gene discussed is PON1; the disease is chronic kidney disease.